Peripheral Interventions

Leading the market in less-invasive treatments for peripheral vascular disease and cancer. Leading the market in less-invasive treatments for peripheral vascular disease and cancer.

As the global market leader in peripheral interventions, we offer the broadest portfolio of solutions for treating peripheral artery disease (PAD), deep vein thrombosis and cancer. We’re dedicated to developing technologies that improve outcomes, cut costs and—most importantly—save the lives and limbs of more people in more places around the world.

Delivering Meaningful Innovation

Advancing the Treatment of PAD. We’re the only company to offer multiple drug-eluting technologies for treating PAD and recently received CE Mark approval for the ELUVIA™ Drug-Eluting Vascular Stent System. In clinical trials, ELUVIA showed one of the highest patency rates ever reported for a peripheral vascular device.

Clearing the Clot. The recent launch of the AngioJet™ ZelanteDVT™ Thrombectomy Catheter further solidifies our position as the market leader in catheter-based procedures to clear dangerous DVT blood clots. We’re investing in new technologies and education to help advance DVT treatment, including ClearingtheClot.com, a website that helps inform patients about their treatment options.

Tumor-Tackling Technologies. We broadened our Interventional Oncology portfolio with the recent acquisition of spherical embolic technologies developed by CeloNova Biosciences, Inc., including the Embozene and Oncozene microspheres. These precisely calibrated spheres are designed to prevent blood flow to the targeted tissue and slow tumor growth.


Conditions We Treat

Peripheral Artery Disease, Deep Vein Thrombosis (DVT), Critical Limb Ischemia, Hypertension, Liver Cancer Peripheral Artery Disease, Deep Vein Thrombosis (DVT), Critical Limb Ischemia, Hypertension, Liver Cancer

  


Solutions We Offer

Peripheral Balloons and Stents, Drug-Eluting Technologies, Thrombectomy Systems, Atherectomy Devices, Coils and Spherical Embolics Peripheral Balloons and Stents, Drug-Eluting Technologies, Thrombectomy Systems, Atherectomy Devices, Coils and Spherical Embolics

Explore AngioJet™ ZelanteDVT™ Thrombectomy Catheter Explore AngioJet™ ZelanteDVT™ Thrombectomy Catheter

Caution: Eluvia Drug-Eluting Vascular Stent System is an investigational device and restricted under U.S. law for investigational use only. Not available for sale in the U.S.

  


Sources

1. US Figure: Gerotziafas GT, et al. Prophylaxis of Venous Thromboembolism in Medical Patients. Curr Opin Pulm Med. 2004; 10:356-365.

Europe Figure: Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 Oct;98(4):756-64.

2. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis  Fowkes, F Gerald R et al. The Lancet , Volume 382 , Issue 9901 , 1329 - 1340.

3. Alvaro Alonso, MD, and Lawrence A. Garcia.  The Costs of Critical Limb Ischemia.  Endovascular Today. 2011; Aug: 32-36

4. American Cancer Society. Key Statistics on Liver Cancer. http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics. Accessed March 23, 2016.

Top